BPI Provides the Solutions Needed to Move Drug Candidates Closer to Approval
The Most Innovative Science
Capitalize on the latest case studies and newest data direct from global thought leaders to improve integration, productivity and cost effectiveness across the bioprocessing spectrum
The Largest Exhibition Devoted to Biomanufacturing
Evaluate next-generation tools and technologies from a global network of solutions providers to accelerate speed, efficiency and ROI
The Right Partners for You
Establish successful partnerships with innovators, suppliers, academia and associations to help you achieve commercial success for your novel therapeutics
Connect and Share Technical, Scientific and Strategic Innovations Across All Phases of Bioprocess Development
1,800+ Bioprocessing Professionals
Achieve clinical and commercial success by collaborating with leading pharma, biotechs, academia and solution providers from across the globe.
225+ Top-Level Speakers
Improve integration, productivity and cost savings in your current line of work by hearing case studies and new data from experts working across the entire bioprocessing spectrum.
160+ Global Exhibitors
Accelerate your drug product to market by accessing innovative products and technologies in the largest exposition hall devoted to biopharmaceutical manufacturing.
Present a Scientific Poster
Highlight your company's latest research findings by presenting a scientific poster, which will be displayed in the exhibit & poster hall during the event. The deadline to submit your poster is August 25, 2017.
Sponsorship & Exhibition Opportunities
Highlight your company's expertise to a global audience of 1800+ bioprocessing scientists and decision makers. A wide variety of options are available to accommodate your company's goals and budget.
How Early-Stage Biotechnology Companies Can Bridge the Investment Gap
There is an investment gap between research funding programs and venture capital investors where early-stage biotechnology companies struggle to obtain funding. As such, companies have to be creative on where they raise funds and how they allocate it. They must also use different strategies to shorten the regulatory process, enabling them to maximize their patent portfolio life. The article examines how companies are using new business models, reducing costs, accelerating development as well as obtaining alternative capital.